CNS Pharmaceuticals, Inc. (CNSP) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US18978H5081
CNS Pharmaceuticals, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -15.99 m USD |
| EBIT | -15.84 m USD |
| Net income | -15.85 m USD |
| Diluted EPS – continuing operations | -35.75 USD |
Full history since 2017, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma; and Berubicin, an investigational anthracycline chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma and brain tumors. The company was incorporated in 2017 and is headquartered in Houston, Texas.
More stocks
- enVVeno Medical Corp (NVNO)
- Blue Star Foods Corp. (BSFC)
- DataMeds AI, Inc. (MEDS)
- TaoWeave, Inc. (TWAV)
- Bio Green Med Solution, Inc. (BGMS)
- America Great Health (AAGH)
- CaliberCos Inc. (CWD)
- Advanced Biomed Inc. (ADVB)
- OLB GROUP, INC. (OLB)
- Cyngn Inc. (CYN)
- MKDWELL Tech Inc. Ordinary Share (MKDW)
- PORTSMOUTH SQUARE INC (PRSI)
Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.